Anti-Cancer Drugs: Trends and Insights from PubMed Records

Background: In recent years, there has been an exponential growth in globalanti-cancer drug research, prompting the necessity for comprehensive analyses of publi-cation output and thematic shifts. Methods: This study utilized a comprehensive set ofPubMed records from 1962 to 2024 and examined growth patterns, content classification,and co-occurrence of key pharmacological and molecular terms. Results: Our resultshighlight an exponential rise in publications, with an annual compound growth rate ofover 14%, influenced by advancements in digital knowledge sharing and novel therapeuticbreakthroughs. A pronounced surge occurred during the COVID-19 pandemic, suggestinga sustained shift in research dynamics. The content analyses revealed a strong emphasis onclassical chemotherapeutic agents—often studied in combination with targeted therapies orimmunotherapies—and a growing focus on immune checkpoint inhibitors and vaccine plat-forms. Furthermore, co-occurrence networks indicated robust links between chemotherapyand supportive care, as well as emerging synergies between immuno-oncology, precisionmedicine approaches. Conclusions: Our study suggests that while novel modalities arereshaping treatment paradigms, chemotherapy remains central, underscoring the value ofintegrative regimens. This trend toward personalized, combination-based strategies indi-cates a transformative era in oncology research, where multidimensional data assessmentis instrumental in guiding future therapeutic innovations.